Education
About Us
Working with TipRanks
Follow Us
DaVita Inc. (CH:TRL)
:TRL
TRL Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
DaVita News
PremiumCompany Announcements
DaVita Holds 2025 Annual Stockholders Meeting
PremiumCompany Announcements
DaVita Completes $1 Billion Senior Notes Offering
PremiumCompany Announcements
DaVita Upsizes Private Offering to $1 Billion
PremiumCompany Announcements
DaVita Announces $750M Senior Notes Offering
Bulls Say, Bears Say
Bulls Say
EarningsOperating income for the first quarter was 5% better than expected, thanks to improved margins.
Product ContributionThe transition of phosphate binders into the Medicare bundle has resulted in a higher benefit and is expected to contribute significantly to operating income.
Revenue GrowthDaVita expects revenue per treatment growth of 4.5% to 5.5% and cost per treatment growth of 6% to 7%, driven significantly by oral phosphate binders.
Bears Say
Operational ChallengesExpectations of lower treatment volumes and lost admissions due to a cyber incident are impacting forecasts.
Volume RecoveryThere is low visibility into volume recovery, which is necessary for long-term operating income growth.
Weather ImpactSevere flu season and winter storms led to a decline in treatments and negatively impacted the overall volumes.
Options Prices
Currently, No data available
---
Ownership Overview
46.04% Insiders
10.26%
Mutual Funds
0.14% Other Institutional Investors
26.19% Public Companies and Individual Investors
TRL FAQ
What was DaVita Inc.’s price range in the past 12 months?
Currently, no data Available
What is DaVita Inc.’s market cap?
Currently, no data Available
When is DaVita Inc.’s upcoming earnings report date?
DaVita Inc.’s upcoming earnings report date is Jul 31, 2025 which is in 35 days.
How were DaVita Inc.’s earnings last quarter?
DaVita Inc. released its earnings results on May 12, 2025. The company reported $1.615 earnings per share for the quarter, beating the consensus estimate of $1.576 by $0.039.
Is DaVita Inc. overvalued?
According to Wall Street analysts DaVita Inc.’s price is currently Undervalued.
Does DaVita Inc. pay dividends?
DaVita Inc. does not currently pay dividends.
What is DaVita Inc.’s EPS estimate?
DaVita Inc.’s EPS estimate is 2.24.
How many shares outstanding does DaVita Inc. have?
Currently, no data Available
What happened to DaVita Inc.’s price movement after its last earnings report?
DaVita Inc. reported an EPS of $1.615 in its last earnings report, beating expectations of $1.576. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of DaVita Inc.?
Currently, no hedge funds are holding shares in CH:TRL
DaVita Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$128.41 (― Downside)
$128.41 (― Downside)
Blogger Sentiment
Bullish
CH:TRL Sentiment 83%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.03%
12-Months-Change
Fundamentals
Return on Equity
260.92%
Trailing 12-Months
Asset Growth
-1.79%
Trailing 12-Months
Company Description
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
TRL Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant achievements in managing a cybersecurity incident and positive contributions from phosphate binders, but also highlighted challenges in treatment volumes and ongoing costs related to the cyber incident.Read More>TRL Revenue Breakdown
88.32% U.S. dialysis
11.68% Ancillary services
TRL Stock 12 Month Forecast
Average Price Target
$128.41
Chemed
―
Fresenius Medical Care
―
Encompass Health
―
Tenet Healthcare
―
Universal Health
―